Vasopressin is an FDA-approved prescription drug substance (marketed as Vasostrict and Pitressin). This monograph documents analytical, chromatographic, and receptor binding specifications strictly for in vitro and preclinical laboratory research.
Molecular Properties
| Parameter | Specification |
|---|---|
| Chemical Name | Arginine Vasopressin / Antidiuretic Hormone (ADH) / Argipressin |
| Amino Acid Sequence | Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (disulfide bridge: Cys1-Cys6) |
| Molecular Formula | C46H65N15O12S2 |
| Molecular Weight | 1084.23 g/mol |
| CAS Number | 113-79-1 (11000-17-2) |
| Chain Length | 9 amino acids |
| Structure Type | Cyclic nonapeptide (6-amino acid ring via disulfide bond + 3-amino acid C-terminal tail) |
Physical Properties
| Property | Specification |
|---|---|
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in water, dilute acetic acid, or saline at ≥1 mg/mL; pH 3.5–5.5 |
| pH (1% solution) | 3.5 – 5.5 (acidic for stability) |
| Hygroscopicity | Moderate; desiccated storage required |
| Solution Stability | Stable at 4°C for 7–10 days at pH 3.5–5.5; degrades at neutral/alkaline pH |
Analytical Specifications
| Test Parameter | Method | Acceptance Criteria |
|---|---|---|
| Purity | RP-HPLC (C18 column, 220 nm) | ≥98.0% |
| Molecular Identity | ESI-MS or MALDI-TOF MS | Confirmed [M+H]+ = 1084.23 ± 0.5 Da; disulfide bridge intact |
| Peptide Content | Amino Acid Analysis | ≥95% |
| Disulfide Bond Integrity | Mass Spectrometry & Bioassay | ≥98% (intact intramolecular Cys1-Cys6 bridge) |
| Endotoxin Level | LAL Assay (USP <85>) | <1.0 EU/mg |
| Acetate Content | Ion Chromatography | ≤5% |
| Water Content | Karl Fischer Titration | ≤5% |
Storage Parameters
- Lyophilized Storage: -20°C to -80°C, desiccated, protected from light
- Reconstituted Storage: 2–8°C for up to 10 days at pH 3.5–5.5; -20°C for up to 3 months
- Reconstitution Protocol: Add 1.0 mL sterile water or 0.1 M acetic acid to 1 mg vial; vortex gently for 30 seconds
- Freeze-Thaw Cycles: Maximum 3 cycles; single-use aliquots recommended
- Light Sensitivity: Moderate; store in amber vials and protect from direct light
In Vitro & Preclinical Model Concentrations
| Application | Concentration / Protocol | Route / Media |
|---|---|---|
| In Vitro Cell Culture | 1–1000 nM | Direct addition to culture media |
| Rodent Models (Antidiuretic / Pressor) | 0.1–5 μg/kg (antidiuretic); 0.5–10 μg/kg (pressor) | Intravenous (IV), Subcutaneous (SC), or Intraperitoneal (IP) |
| Water Retention Studies (V2) | 0.1–1 μg/kg | Intravenous (IV) preferred |
| Vascular Studies (V1a) | 1–10 μg/kg | IV bolus |
| Behavioral/Stress Studies | 0.5–5 μg/animal (intranasal); 0.1–1 μg/kg (IV) | Intranasal or IV (30–60 min pre-testing) |
Unit Conversion Note: USP activity is typically expressed as Units (U); 1 mg ≈ 400–500 USP units.
Key Research Studies
| Year | Study Focus | Key Findings |
|---|---|---|
| 1954 | Structure elucidation and synthesis | Du Vigneaud determined vasopressin structure; differs from oxytocin by 2 amino acids (positions 3 and 8); Cys1-Cys6 disulfide bridge essential for activity; synthesized with full biological potency |
| 1992–1994 | Receptor subtype cloning | Identified three receptor subtypes: V1a (vascular smooth muscle, liver), V1b/V3 (pituitary corticotrophs), V2 (renal collecting duct); differential Kd values: V1a ~1 nM, V1b ~1.5 nM, V2 ~0.5 nM |
| 2005 | Central nervous system effects on social behavior | Brain V1a receptor activation modulated social recognition, aggression, and pair bonding in rodent models; species-specific V1a receptor expression patterns correlated with monogamous vs. polygamous behavior |
| 2010 | Structure-activity relationships across receptor subtypes | Position 8 (Arg) critical for V2 selectivity; position 3 (Phe) enhances V1 selectivity vs. oxytocin receptor; C-terminal Gly-NH2 absolutely required with removal reducing potency >1000-fold |
Mechanism of Action
- V1a Receptor (Vascular): Gq-coupled → PLC → IP3/DAG → Ca2+ mobilization → vascular smooth muscle contraction → vasoconstriction and blood pressure elevation.
- V1b Receptor (Pituitary): Gq-coupled on anterior pituitary corticotrophs → ACTH release → modulation of HPA axis and stress response.
- V2 Receptor (Renal): Gs-coupled on collecting duct principal cells → cAMP/PKA → aquaporin-2 insertion into apical membrane → water reabsorption (antidiuretic effect).
- Central Nervous System Effects: Modulates social recognition, circadian rhythms, temperature regulation, and stress response; V1a receptors expressed in lateral septum, hippocampus, and amygdala.
- Half-Life: 5–20 minutes (IV); metabolized by vasopressinases (aminopeptidases) in liver and kidney.
Receptor Selectivity Profile
| Receptor Subtype | G-Protein Coupling | Primary Tissue Distribution | Binding Affinity (Kd) |
|---|---|---|---|
| V1aR | Gq → PLC → Ca2+ | Vascular smooth muscle, liver, CNS | 0.5 – 2 nM |
| V1bR (V3R) | Gq → PLC → Ca2+ | Anterior pituitary (corticotrophs), CNS | 1 – 3 nM |
| V2R | Gs → adenylyl cyclase → cAMP | Kidney collecting duct, endothelium | 0.3 – 1 nM |
| Oxytocin Receptor (OXTR) | Gq → PLC → Ca2+ | Uterus, mammary, CNS | 50 – 500 nM (low affinity) |
Quality Control Parameters
| Test Method | Acceptance Criteria |
|---|---|
| Appearance (visual) | White to off-white powder; no aggregation or discoloration |
| Disulfide Bridge Confirmation | ESI-MS shows intact cyclic structure; no reduced form detected |
| RP-HPLC (purity) | Main peak ≥98.0%; no single impurity >0.5% |
| Biological Activity (USP) | ≥400 USP units/mg (rat pressor assay) |
| Amino Acid Analysis | Confirmed sequence with Arg at position 8 |
Comparative Structural Analysis
Arginine vasopressin (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2) differs from oxytocin (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2) solely at positions 3 (Phe3 vs. Ile3, conferring V1 receptor selectivity) and 8 (Arg8 vs. Leu8, conferring V2 receptor selectivity and antidiuretic activity), while the Cys1–Cys6 disulfide bridge and C-terminal Gly-NH2 are essential for biological activity across both hormones.
Primary Scientific References
- du Vigneaud V, Lawler HC, Popenoe EA. Enzymatic cleavage of glycinamide from vasopressin and a proposed structure for this pressor-antidiuretic hormone of the posterior pituitary. J Biol Chem. 1953;205(2):949-957. JBC Reference
- Thibonnier M, Coles P, Thibonnier A, Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol. 2001;41:175-202. DOI: 10.1146/annurev.pharmtox.41.1.175
- National Center for Biotechnology Information. PubChem Compound Summary for Vasopressin. PubChem: Vasopressin
